Rapid diagnosis reagent for mild and moderate brain injuries, kit containing same and preparation and detection methods of kit

Abstract

The invention belongs to the technical field of immunoassays, and in particular relates to a rapid diagnostic reagent for mild to moderate brain damage, a kit containing the reagent, and methods for preparing and detecting the kit. The reagent and the kit include monoclonal capture antibodies prepared by S100, GFAP, and UCHL1 respectively; the kit also includes detection antibodies, polyclonal antibodies prepared by S100, GFAP, and UCHL1 respectively. The beneficial effects of the present invention are as follows: it can comprehensively detect mild and moderate brain damage, can better judge the physiological and structural changes after brain damage, better carry out differential diagnosis on patients with moderate and mild brain damage, and has high sensitivity and accuracy Strong features, its sensitivity and accuracy are above 96%.

Description

technical field [0001] The invention belongs to the technical field of immunoassays, and in particular relates to a rapid diagnostic reagent for mild to moderate brain damage, a kit containing the reagent, and a preparation and detection method for the kit. Background technique [0002] Traumatic brain injury (TBI) is currently a major public health problem causing death and disability worldwide. There are 235×103 cases of non-fatal craniocerebral trauma hospitalized in the United States every year, and 43.30% of them are left with different degrees of disability. The annual incidence of traumatic brain injury in my country is 783 cases per 100,000 people, of which severe traumatic brain trauma with Glasgow Coma Scale (GCS) score ≤ 8 and post-traumatic amnesia (PTA) > 24 h accounts for about 10%. [0003] More than 1.5 million children and adults suffer concussions in the United States each year, and thousands of military personnel worldwide suffer from mild traumatic br...

AI Technical Summary

Problems solved by technology

However, based on the practical experience of the inventors of the present application, due to the existence of individual differences, the clinical trials of the above-mentioned single factor or two factors all failed, and the combination of multiple factors also has great uncertainty.

The above-mentioned patent is only a layout patent, and there is no detection method that can exclude individual differences in the prior art

Images